Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories (RDY) maintains its position as a global pharmaceutical innovator through strategic developments in generic medicines, biosimilars, and active pharmaceutical ingredients. This news hub provides investors and industry professionals with essential updates on corporate milestones, regulatory filings, and market expansions.
Access real-time information about earnings announcements, partnership agreements, and product pipeline advancements. Our curated collection features official press releases covering FDA approvals, manufacturing facility certifications, and therapeutic area breakthroughs in oncology and gastroenterology.
Monitor critical updates including patent litigation outcomes, emerging market entries, and sustainability initiatives. The repository serves as a reliable resource for understanding RDY's operational strategies and quality compliance across 75+ countries.
Bookmark this page for streamlined access to verified updates about Dr. Reddy's Laboratories. Check regularly for insights into biosimilar developments, API production innovations, and financial performance indicators shaping the global pharmaceutical landscape.
Dr. Reddy’s Laboratories Ltd. announced a definitive agreement with Citius Pharmaceuticals to sell all rights to E7777, an IL-2-diphtheria toxin fusion protein, and related assets. The transaction will grant Dr. Reddy’s an upfront payment of
Dr. Reddy's Laboratories has launched Reddy-Lenalidomide, a generic version of Revlimid, in Canada after receiving approval from Health Canada. This launch is significant as it aims to provide affordable treatment options for Multiple Myeloma and Myelodysplastic Syndrome (MDS) patients. The medication is available in multiple strengths and is part of a broader initiative to enhance patient access through the Reddy2Assist Platform. However, Reddy-Lenalidomide comes with important warnings and limitations, especially regarding its use in pregnant women and potential severe side effects.
Dr. Reddy’s Laboratories has launched a generic version of Librax® in the U.S., specifically Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, available in 5 mg/2.5 mg strength. This product, approved by the U.S. FDA, targets a market that generated approximately $105.9 million in sales over the last twelve months. The capsules are sold in bottles of 100. The launch aims to provide affordable medication options while addressing the significant risks associated with benzodiazepine use, including potential addiction and withdrawal reactions.
Dr. Reddy’s Laboratories has entered into an asset purchase agreement to sell its U.S. and Canada rights for ELYXYB (celecoxib oral solution) to BioDelivery Sciences International for $6 million upfront and $9 million a year later. The transaction is pending customary closing conditions. ELYXYB is indicated for acute migraine treatment. CEO Erez Israeli highlighted this sale as a reaffirmation of their commitment to innovative products addressing unmet patient needs, expressing confidence in BDSI's capabilities.
Dr. Reddy’s Laboratories Ltd. has announced the re-launch of its OTC Naproxen Sodium Tablets USP, 220 mg in the U.S., approved by the FDA. This product is a store-brand equivalent of Aleve® and serves as a pain reliever and fever reducer. CEO Marc Kikuchi highlighted its significance in the company's Pain/Analgesics portfolio, emphasizing the robust supply chain for consistent product availability. Naproxen Sodium had U.S. retail sales of around $316 million as of July 2021, and the tablets will come in various pack sizes for consumer convenience.
Dr. Reddy's Laboratories has filed its Annual Report on Form 20-F with the SEC for the fiscal year ending March 31, 2021. The report includes consolidated financial statements prepared in accordance with IFRS. Shareholders can access the report online at www.drreddys.com or request a hard copy. The company operates through three key divisions, focusing on affordable and innovative pharmaceuticals in various therapeutic areas across global markets including the USA, India, and Europe.
Dr. Reddy's Laboratories Ltd. has launched Icosapent Ethyl Capsules (1 gram), approved by the U.S. FDA, indicated for lowering triglyceride levels in patients with severe hypertriglyceridemia (≥ 500 mg/dL). The product, available in bottles of 120 capsules, is not approved for reducing cardiovascular risks associated with elevated triglyceride levels. Important safety information includes potential risks of heart arrhythmias, allergic reactions, and bleeding, particularly in patients on anticoagulants. Full prescribing information can be accessed here.
Global Response Aid (GRA) announced significant global sales of its anti-viral drug Avigan®/Reeqonus™ for treating COVID-19, totaling $33 million in revenue. The company has partnered with Dr. Reddy's (NYSE: RDY) and initiated a global Phase 3 clinical trial, reporting a positive interim outlook. Countries including India, Thailand, and Malaysia have approved Avigan® for treatment, with a notable order of over 65 million tablets from the Japanese government. GRA's CEO expressed optimism about Avigan®'s role in combating the pandemic.
Dr. Reddy’s Laboratories Ltd. has launched Albendazole Tablets, USP, a generic equivalent of Albenza Tablets, approved by the USFDA. This product comes in 200 mg tablets and is available in bottle sizes of two. The Albenza brand, whose U.S. sales reached approximately $27 million over the last twelve months, is owned by Glaxosmithkline. The launch aims to expand Dr. Reddy’s portfolio in the generics market, enhancing accessibility to affordable medications.
Dr. Reddy's Laboratories (NYSE: RDY) has received approval from the Drug Controller General of India (DCGI) to import the Sputnik V vaccine for emergency use in India. This follows their collaboration with the Russian Direct Investment Fund (RDIF) since September 2020 to conduct clinical trials. Dr. Reddy's is now contributing to India's vaccination efforts amid rising COVID-19 cases. Sputnik V, which boasts an efficacy rate of 91.6%, has been approved in 60 countries globally and ranks second in vaccine approvals worldwide.
